This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at firstname.lastname@example.org or call 800-767-3771 ext. 9339.
For Immediate Release
Chicago, IL – January 31, 2013 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Colgate-Palmolive Company (CL - Analyst Report), Procter & Gamble Company (PG - Analyst Report), The Clorox Company (CLX - Analyst Report), Inter Perfums Inc. (IPAR - Snapshot Report) and The Bank of New York Mellon Corporation (BK - Analyst Report).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Wednesday’s Analyst Blog:
Will Colgate-Palmolive Beat in 4Q?
World’s leading consumer goods dealer, Colgate-Palmolive Company (CL - Analyst Report) is likely to beat the expectations when it reports its fiscal 2012 fourth-quarter results on Jan 31.
Why a Likely Positive Surprise?
Our proven model shows that Colgate-Palmolive may beat the earnings because it has the right combination of two key components – Positive Earnings ESP (Read: Zacks Earnings ESP: A Better Method) and a Zacks Rank #2.
Zacks ESP: Colgate-Palmolive currently has an Earnings ESP of +1.43%. This is because the Most Accurate Estimate stands at $1.42, while the Zacks Consensus Estimate is pegged at $1.40.
Zacks #2 Rank (Buy): Note that stocks with Zacks Rank #1, #2 and #3 have significantly higher chances of beating the earnings. The sell rated stocks (#4 and #5) should never be considered going into an earnings announcement.
The combination of Colgate-Palmolive’s Zacks Rank #2 (Buy) and Earnings ESP of +1.43% make us confident regarding a positive earnings beat by the company on Jan 31.
What is Driving the Better-than-Expected Earnings?
We believe that the company’s strategic acquisition and divestment activities, along with sustained focus on product innovation, provide it a platform to take advantage of growth opportunities, and thereby augment profitability.
The company has met as well as surpassed the Zacks Consensus Estimate in trailing four quarters with an average surprise of approximately 0.8%.
Other Stocks to Consider
Colgate-Palmolive is not the only firm looking up this earnings season. The following companies – Colgate’s industry peers – are also likely to beat the earnings in the to-be-reported quarter:
Procter & Gamble Company (PG - Analyst Report) with Earnings ESP of +2.08% and a Zacks Rank #2 (Buy).
The Clorox Company (CLX - Analyst Report) with Earnings ESP of +1.24% and a Zacks Rank #3 (Hold).
Inter Perfums Inc. (IPAR - Snapshot Report) has Earnings ESP of +13.33% and carries a Zacks Rank #3 (Hold).
BNY Mellon’s Dismissal Plea Refused
The Supreme Court of the State of New York has rejected a dismissal plea of The Bank of New York Mellon Corporation (BK - Analyst Report). A lawsuit was filed by The Salvation Army accusing BNY Mellon of mismanaging funds.
The New York Judge has sustained three out four claims in the Salvation Army's lawsuit against BNY Mellon's gross negligence, breach of fiduciary duty and breach of contract. However, the claim for negligent misrepresentation was dismissed. The Salvation Army is seeking $22 million in compensation.
In Apr 2011, the southern division of the Salvation Army had filed the lawsuit alleging gross ignorance on part of BNY Mellon regarding the investment of the charity's funds. The Salvation Army's instructions of investing in less risky avenues were not followed by the bank. Rather, BNY Mellon went ahead and invested funds in perilous mortgage-backed securities. Consequently, when the markets collapsed, the Salvation Army suffered huge losses.
In its defense, BNY Mellon was quick to point that the investment strategy at during that particular period was prudent enough and it had meticulously executed the investment of the charity's funds. Further, the bank added that it was willing to challenge the charges in the court.
Presently, BNY Mellon is not the only bank facing problems over investment in mortgage-backed securities prior to 2008 financial crisis.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339